TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tonix Pharmaceuticals Holding Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.73−0.31 (-5.13%)
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$12.89 (−69.23%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Tonix Pharmaceuticals Holding Corp. grew revenue 196.0% to $29.10M over the twelve months to Jun 30, 2026. Free cash flow was -$158.11M.
Revenue
$29.10M
+196.0% vs. a year earlier
Operating income
-$165.43M
TTM Q2 2026
Free cash flow
-$158.11M
TTM Q2 2026
EPS, diluted
-$12.92
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $95.32M
- P/E ratio
- –
- Price to sales
- 3.28
- Price to book
- 0.43
- Dividend yield
- –
- Free cash flow yield
- -165.87%
Fundamentals
- Revenue
- $29.10M
- Net income
- -$159.67M
- EPS, diluted
- -$12.92
- Free cash flow
- -$158.11M
- Book value per share
- $13.36
- Diluted shares
- 17M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$29.10M+196.0% YoY
Gross profit
$24.40M+747.7% YoY
Operating income
-$165.43M
Net income
-$159.67M
EPS, diluted
-$12.92
Free cash flow
-$158.11M
Reported periodTrailing twelve months